- Atlas
- Medicine & Health
- Clinical Pharmacology
Clinical Pharmacology
Clinical pharmacology is the branch of medicine that studies drugs in human beings: how a dose gets into the body and where it goes, what it does to the body and to the disease, why the same medicine helps one patient and harms another, and how all of this can be measured, predicted, and taught.
7 frameworks, from 1920 to today · Pharmacology · Medicine & Health
Overview
Clinical pharmacology is the branch of medicine that studies drugs in human beings: how a dose gets into the body and where it goes, what it does to the body and to the disease, why the same medicine helps one patient and harms another, and how all of this can be measured, predicted, and taught1. It sits between laboratory pharmacology, which works with molecules, cells, and animals, and medical practice, which must decide what to give a particular patient on a particular day. Its central problem is variability. A dose that controls a disease in one person may do nothing in a second and poison a third, and the field's history is largely the story of learning to explain, measure, and manage that variability rather than ignore it.
From materia medica to the measured dose
For most of history, medicines were judged by tradition and authority1. The materia medica—the accumulated catalogue of substances and their uses—was the practitioner's working knowledge, and doses were inherited rules of thumb. The change came in the eighteenth and nineteenth centuries, when experimental physiology and chemistry began to ask what a substance actually does1. François Magendie's experiments in the early 1800s on the action of drugs such as strychnine and morphine, and later Claude Bernard's work on curare and on the site of action of poisons, established that a drug's effect could be traced to a specific tissue and a specific mechanism. This was the beginning of pharmacology as an experimental science, and it made the clinical question sharper: if a drug acts on a known tissue, what concentration must reach that tissue to produce the effect, and how does the body deliver it?
The nineteenth-century clinic supplied the other half. Physicians such as William Withering, whose 1785 account of foxglove (digitalis) in dropsy described both its benefits and its dangers, and later clinicians who used morphine, quinine, and anaesthetics, learned by observation that dose, timing, and the patient's condition mattered enormously. But without a way to measure drug concentrations in the body, these observations remained clinical impressions.
Pharmacokinetics: what the body does to the drug
The decisive turn came in the mid-twentieth century, when pharmacologists began to treat the body as a system that handles a drug according to measurable rules. The key quantities were absorption (how a drug gets from the gut or injection site into the bloodstream), distribution (where it goes in the body), metabolism (how the body chemically alters it), and excretion (how it leaves)1. Together these became known as pharmacokinetics, conventionally summarized as "what the body does to the drug," in contrast to pharmacodynamics, "what the drug does to the body."234
The conceptual breakthrough was the idea of clearance: the volume of blood or plasma from which a drug is completely removed per unit time5. Clearance, together with the volume of distribution (a theoretical volume relating the amount of drug in the body to its concentration in plasma), allowed clinicians to predict how a dose would translate into a concentration and how long it would persist. The compartmental model, which treats the body as one or more well-mixed compartments, gave these ideas mathematical form. By the 1960s and 1970s, pharmacokinetics had become a quantitative discipline, and its clinical application—adjusting doses for patients with kidney or liver disease, for the elderly, for children—became a core clinical skill.
Pharmacodynamics: what the drug does, and the dose–response relationship
Parallel to pharmacokinetics, pharmacodynamics developed the language of receptors and dose–response3. The receptor theory of the late nineteenth and early twentieth centuries—associated with Paul Ehrlich's "magic bullet" idea and with the quantitative work of A. J. Clark in the 1920s and 1930s—held that drugs act by binding to specific cellular targets, and that the magnitude of effect depends on how much of the target is occupied. Clark's experiments on the action of acetylcholine on frog heart showed that the relationship between drug concentration and effect followed a characteristic curve, saturating at high concentrations. This gave clinical pharmacology a way to think about potency (how much drug is needed for a given effect), efficacy (the maximum effect achievable), and the therapeutic window (the range of concentrations between the desired effect and toxicity)6.
The practical consequence was that the same drug could be given at different doses to different patients and produce different effects, and that the effect was a function of concentration at the target, not simply of the dose swallowed. This linked pharmacodynamics back to pharmacokinetics: to predict an effect, one needed to know both the concentration–effect relationship and the concentration–time course.
The randomized controlled trial and the birth of clinical evidence
The mid-twentieth century also transformed how clinical pharmacology judged whether a drug worked at all. Before the Second World War, therapeutic claims were often based on case series and clinical impression, which were vulnerable to bias and to the natural course of disease. The randomized controlled trial (RCT)—in which patients are allocated by chance to receive the drug or a control, and outcomes are compared—provided a way to isolate the drug's effect from expectation, confounding, and chance7. The British Medical Research Council's 1948 trial of streptomycin in pulmonary tuberculosis, led by Austin Bradford Hill and Marc Daniels, is often cited as a landmark of the modern RCT, and it established the template: randomization, a control group, and blinded assessment where possible.
For clinical pharmacology, the RCT was both a tool and a discipline. It forced the field to define outcomes, to calculate sample sizes, and to confront the difference between statistical significance and clinical importance. It also created the ethical framework of the modern trial—informed consent, independent oversight, and the principle that a new treatment must be tested against the best available alternative. The thalidomide tragedy of the late 1950s and early 1960s, in which a sedative marketed as safe in pregnancy caused severe birth defects, made the stakes unmistakable and drove the creation of modern drug regulation.
Regulatory drug development: from thalidomide to the modern pathway
Before thalidomide, drug approval in most countries was a loose affair. The United States' 1938 Food, Drug, and Cosmetic Act required proof of safety but not efficacy; the 1962 Kefauver–Harris amendments, passed in the wake of thalidomide, required that a new drug be shown effective as well as safe before marketing. This created the modern phased development pathway: preclinical testing in animals, then Phase I trials in small numbers of healthy volunteers to establish safety and pharmacokinetics, Phase II trials in patients to look for efficacy and dose, and Phase III trials in larger patient populations to confirm benefit and detect less common harms. The randomized, controlled, often blinded Phase III trial became the evidentiary standard, and regulatory agencies—the U.S. Food and Drug Administration, the UK's Committee on Safety of Drugs (later the Medicines Control Agency and then the MHRA), and equivalent bodies elsewhere—became gatekeepers with the power to demand data.
Clinical pharmacologists became central to this enterprise. They designed the early-phase studies, interpreted the pharmacokinetic data, and advised on dose selection. The field also developed the discipline of therapeutic drug monitoring: measuring drug concentrations in patients' blood to individualize dosing, especially for drugs with narrow therapeutic windows such as digoxin, lithium, phenytoin, and the aminoglycoside antibiotics. Monitoring turned the abstract idea of a therapeutic range into a bedside tool, though it also taught that concentration is only one part of the picture—the patient's clinical state, adherence, and the drug's pharmacodynamics matter too8.
Pharmacogenetics: why patients differ
The observation that patients respond differently to the same drug is ancient, but the explanation began to take shape in the 1950s. In 1957, the German physician Friedrich Vogel coined the term "pharmacogenetics" for the study of inherited differences in drug response. Around the same time, clinicians noticed that some patients given the antimalarial primaquine developed severe haemolysis, and that this was linked to an inherited deficiency of the enzyme glucose-6-phosphate dehydrogenase. Other early examples included the prolonged paralysis caused by the muscle relaxant succinylcholine in people with an inherited variant of the enzyme pseudocholinesterase, and the differing rates at which people metabolize the anti-tuberculosis drug isoniazid—fast and slow acetylators, a difference traced to variants in the enzyme N-acetyltransferase.
These findings established a principle: genetic variation in drug-metabolizing enzymes, transporters, and targets can produce clinically important differences in drug exposure and effect. The field grew slowly at first, limited by the technology available to genotype patients. The sequencing of the human genome and the arrival of cheap, high-throughput genotyping in the early 2000s transformed it into pharmacogenomics, the study of how the whole genome influences drug response. Clinical implementation followed unevenly: some tests, such as HLA-B*57:01 screening to prevent abacavir hypersensitivity and TPMT genotyping before thiopurine therapy, became standard, while many others remain research tools. The field's promise—matching drug and dose to genotype—is real but still only partly realized.
Population pharmacokinetics and Bayesian individualization
As pharmacokinetics matured, clinicians recognized that a single "average" patient did not exist. Patients differ in weight, age, kidney function, concomitant medications, and genetics, and these differences change clearance and volume of distribution. Population pharmacokinetics, developed from the 1970s onward, used statistical models to describe how these covariates explain variability across a population, and to estimate the typical values and the spread around them. The approach relied on nonlinear mixed-effects modeling, which could analyze sparse data—a few blood samples from many patients—rather than requiring rich sampling from each individual.
This led to Bayesian dose individualization: using a population model as a prior, then updating it with a patient's own measured drug concentrations to estimate that patient's likely pharmacokinetic parameters and adjust the dose accordingly9. The method, formalized in the 1970s and 1980s by workers such as Lewis Sheiner and Stuart Beal, who developed the NONMEM software for population modeling, allowed therapeutic drug monitoring to become genuinely individualized rather than rule-based. It is now used routinely in transplant medicine (for immunosuppressants such as tacrolimus), in oncology, and in the dosing of aminoglycosides and vancomycin.
The present: precision, regulation, and the unfinished questions
Clinical pharmacology today is a mature but still-changing field. Its core methods—pharmacokinetic and pharmacodynamic modeling, the randomized trial, therapeutic drug monitoring, population analysis, and pharmacogenomic testing—descend directly from the turning points above. The regulatory pathway is global and highly standardized, though debates continue about how to speed access to promising drugs without sacrificing evidence. The rise of biologics and gene therapies has stretched the old pharmacokinetic frameworks, which were built for small molecules. Pharmacogenomics is being folded into routine prescribing through clinical guidelines, but evidence that genotype-guided dosing improves outcomes remains incomplete for many drug–gene pairs. And the problem that started the field—why the same dose affects people differently—is still not fully solved: adherence, drug interactions, disease severity, and environmental factors all contribute, and the dream of predicting an individual's response before the first dose remains partly a research goal. What has changed is that clinical pharmacology now has the tools to measure, model, and manage that variability, and a body of evidence and regulation that makes the measured dose, rather than the inherited rule, the standard of care.
References
- Clinical pharmacology (introduction, History, Branches), Wikipedia
- Pharmacology, Wikipedia
- Pharmacodynamics, Wikipedia
- Pharmacokinetics, Wikipedia
- Clearance (pharmacology), Wikipedia
- Therapeutic index, Wikipedia
- Randomized controlled trial, Wikipedia
- Therapeutic drug monitoring, Wikipedia
- Model-Informed Precision Dosing, Wikipedia
The frameworks of Clinical Pharmacology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1920-Present
- 1948-Present
Randomized controlled trial
How can we tell whether a treatment truly works?
- 1950-Present
- 1957-Present
- 1960-Present
Therapeutic drug monitoring
How can dosing be tailored to the individual patient?
- 1962-Present
- 1970-Present
Population pharmacokinetics and Bayesian individualization
How can sparse data predict the right dose for one patient?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Drug development influenced by Randomized controlled trial
The randomized controlled trial supplied the evidentiary standard that the modern phased drug-development pathway was built around. After the 1962 Kefauver–Harris amendments required proof of efficacy, the randomized, controlled, often blinded Phase III trial became the regulatory benchmark for approval.
Carried by Kefauver–Harris Amendments (1962).
Therapeutic drug monitoring grew out of Pharmacokinetics
Therapeutic drug monitoring grew directly out of pharmacokinetics: clearance, volume of distribution and the compartmental model let clinicians predict how a dose becomes a plasma concentration, and monitoring measured that concentration to individualize dosing. The narrow-window drugs it targeted—digoxin, lithium, phenytoin, aminoglycosides—were understood through pharmacokinetic reasoning.
Population pharmacokinetics and Bayesian individualization grew out of Pharmacokinetics
Population pharmacokinetics generalized the compartmental and clearance models from the individual to the population, estimating typical values and between-patient variability. Bayesian individualization then used those population estimates as priors to adjust dosing for a particular patient from sparse measurements.
Carried by Lewis Sheiner.
Therapeutic drug monitoring influenced by Pharmacodynamics
The pharmacodynamic idea of a therapeutic window—the concentration range between desired effect and toxicity—was the concept that made measuring blood concentrations clinically meaningful. Therapeutic drug monitoring turned that dose–response reasoning into a bedside tool for drugs with narrow windows.
Pharmacogenomics influenced by Pharmacokinetics
Pharmacokinetic concepts of metabolism and clearance framed the early pharmacogenetic observations: fast and slow acetylators of isoniazid differed in how they metabolized the drug, and pseudocholinesterase variants altered the breakdown of succinylcholine. Inherited differences were understood as differences in the body's handling of a drug.
Drug development influenced by Pharmacokinetics
Pharmacokinetics gave drug development its early-phase tools: Phase I studies in healthy volunteers were designed to establish safety and pharmacokinetics, and clinical pharmacologists interpreted clearance and volume-of-distribution data to select doses for later phases.
Population pharmacokinetics and Bayesian individualization influenced by Therapeutic drug monitoring
Therapeutic drug monitoring created the practical problem of interpreting sparse, noisy concentration measurements in individual patients. Bayesian individualization was developed as a formal method for doing exactly that, combining a population model with the patient's measured levels.
Carried by Lewis Sheiner.
Pharmacogenomics influenced by Pharmacodynamics
Pharmacodynamics posed the question of why the same concentration produces different effects in different patients, and inherited differences in drug targets and enzymes became one answer. The receptor and dose–response framework gave pharmacogenetics its vocabulary of variable response.
Beyond the field
Where Clinical Pharmacology's ideas came from in other fields, and what they led to there: the strongest 12 of 58 links.
Pharmacodynamics grew out of Experimental physiology and site-of-action pharmacology in Pharmacodynamics
Site-of-action pharmacology, built on experimental physiology by Magendie, Bernard and Langley, is the direct parent of pharmacodynamics: it established that drugs act at specific bodily sites. Pharmacodynamics generalized this into the study of drug action mechanisms.
Carried by Claude Bernard; John Newport Langley.
Pharmacodynamics influenced by Receptor theory in Pharmacology
Pharmacology's receptor theory, from Langley and Ehrlich through Clark's quantitative treatment, provided pharmacodynamics with its central explanatory framework of drug-receptor interaction.
Carried by A. J. Clark; John Newport Langley.
Pharmacodynamics grew out of Pharmacology in Pharmacy
Pharmacodynamics emerged as the branch of pharmacology concerned with how drugs act on the body, complementing pharmacology's earlier focus on sources and preparations. The receptor work of Ehrlich and Langley gave it its central explanatory concept.
Carried by Paul Ehrlich; John Newport Langley.
Pharmacodynamics influenced by Receptor theory in Medicinal Chemistry
Receptor theory supplied pharmacodynamics with its core model of drug action: drugs act by binding specific receptive substances, as formulated by Langley and Ehrlich and later quantified by Clark. This concept is the backbone of pharmacodynamic reasoning.
Carried by John Newport Langley; Paul Ehrlich; A. J. Clark.
Pharmacodynamics influenced PKPD model in Translational Pharmacology
Pharmacodynamics supplied the receptor and dose-response concepts that the PKPD model couples to concentration-time data; the integrated model is built on pharmacodynamic theory.
Pharmacokinetics led to Biopharmaceutics in Pharmaceutics
Biopharmaceutics grew out of pharmacokinetics as applied in clinical pharmacology, where plasma concentration measurements after dosing exposed formulation effects on absorption. The clinical pharmacokinetic methods were the direct source of biopharmaceutic study.
Pharmacokinetics influenced Modified-release dosage in Pharmaceutics
Modified-release dosage was built on pharmacokinetics: plasma concentration-time curves and half-life data gave the rationale for sustaining drug levels. The design of sustained-release forms was driven by pharmacokinetic measurement of absorption and elimination.
Pharmacokinetics grew out of Pharmacology in Pharmacy
Pharmacokinetics grew out of pharmacology as the quantitative study of drug absorption, distribution, metabolism and excretion, formalized in the 1950s by Dost and others. It is a branch of the parent discipline.
Carried by F. H. Dost.
Pharmacokinetics led to Clinical Pharmacokinetics in Clinical Pharmacy
Clinical pharmacokinetics grew directly out of pharmacokinetics as a general pharmacological science, applying its compartment models and clearance concepts to individual patients; the journal Clinical Pharmacokinetics was founded in 1976 as the specialty's organ.
Carried by Clinical Pharmacokinetics (1976).
Pharmacogenomics grew out of Classical Pharmacogenetics in Pharmacogenomics
Classical pharmacogenetics, the study of inherited single-gene variation in drug response from the 1950s, is the direct parent of pharmacogenomics. The latter extended the same questions to genome-wide variation and drug discovery.
Carried by Friedrich Vogel; Arno Motulsky.
Population pharmacokinetics and Bayesian individualization influenced Bayesian pharmacometrics in Pharmacometrics
Bayesian individualisation of population pharmacokinetic models, using priors and MAP estimation, is the direct methodological ancestor of Bayesian pharmacometrics.
Carried by Lewis Sheiner.
Population pharmacokinetics and Bayesian individualization led to Model-Informed Precision Dosing in Pharmacometrics
Model-informed precision dosing grew directly out of population pharmacokinetics with Bayesian individualization, using prior population models and patient concentrations to compute individualized doses.
Carried by Population pharmacokinetics and Bayesian individualization.

Clinical Pharmacology is a planet in Nousfarer
Its city has a tower for each of these 7 frameworks. Land, walk in, and climb one concept at a time.
Land on Clinical PharmacologyRelated fields
Fields its ideas are linked to
- Pharmacology 12 links
- Pharmacometrics 10 links
- Translational Pharmacology 6 links
- Pharmacy 6 links
- Pharmaceutics 4 links
- Comparative Effectiveness Research 2 links
- Pharmacodynamics 2 links
- Clinical Pharmacy 2 links
- Engineering Physiology 1 link
- Medicinal Chemistry 1 link
- Impact Evaluation 1 link
- Environmental Toxicology 1 link
More in Pharmacology
- Drug Discovery
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- Pharmacometrics
- Pharmacovigilance
- Receptor Theory And Signal Transduction
- Toxicology
- Translational Pharmacology
See where Clinical Pharmacology sits on the Map of Human Knowledge